Sanofi France confirms atorvastatin accord with Pfizer
This article was originally published in Scrip
Sanofi France has confirmed to Scrip that it has signed a licensing deal with Pfizer to manufacture the cholesterol lowering blockbuster atorvastatin in France. The company further confirmed that it will not launch Tahor, the name for its version of the drug, until after the Lipitor patent has expired fully in France on 7 May 2012. While the US patent for Lipitor expires in November 2011, Pfizer secured a six month extension to its European exclusivity through a paediatric supplementary protection certificate.